Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 6
1953 4
1954 5
1955 8
1956 6
1957 8
1958 9
1959 13
1960 8
1961 14
1962 2
1965 8
1966 21
1967 12
1968 17
1969 19
1970 10
1971 13
1972 21
1973 6
1974 14
1975 26
1976 23
1977 33
1978 33
1979 24
1980 20
1981 25
1982 35
1983 40
1984 39
1985 54
1986 52
1987 60
1988 54
1989 86
1990 53
1991 46
1992 67
1993 55
1994 63
1995 81
1996 68
1997 77
1998 78
1999 87
2000 61
2001 91
2002 112
2003 112
2004 135
2005 114
2006 129
2007 153
2008 126
2009 141
2010 154
2011 172
2012 183
2013 170
2014 187
2015 203
2016 213
2017 194
2018 212
2019 89
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

4,091 results
Results by year
Filters applied: . Clear all
Page 1
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Palumbo A, et al. J Clin Oncol 2015. PMID 26240224 Free PMC article.
PURPOSE: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. ...
PURPOSE: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify pati …
Smoldering multiple myeloma.
Gao M, et al. Biomed Res Int 2015 - Review. PMID 26000300 Free PMC article.
Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of multiple myeloma (MM) characterized by clonal bone marrow plasma cells (BMPC) ≥ 10% and/or M protein level ≥ 30 g/L in the absence of end organ damage. ...
Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of multiple myeloma (MM) characterized by c …
Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
Berger N, et al. Adv Exp Med Biol 2018 - Review. PMID 30411265
Multiple Myeloma (MM) therapy has evolved rapidly over the past decade. With current multidrug combinations and autologous transplant, rates of overall response exceed 90% and complete response (CR) more than 50% in some studies. ...These methods have provided a means to quantitatively assess residual disease and accurately prognosticate PFS and OS in myeloma. ...
Multiple Myeloma (MM) therapy has evolved rapidly over the past decade. With current multidrug combinations and autologous tra
International uniform response criteria for multiple myeloma.
Durie BG, et al. Leukemia 2006. PMID 16855634
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. ...It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma....
New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone M …
Monitoring multiple myeloma.
Udd KA, et al. Clin Adv Hematol Oncol 2017. PMID 29315287
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated plasma cells. ...
Multiple myeloma (MM) is a B-cell malignancy characterized by the accumulation in bone marrow of terminally differentiated pla
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.
Kumar SK, et al. Leukemia 2014. PMID 24157580 Free PMC article.
Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. ...
Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not cl …
Multiple myeloma.
Collins CD. Cancer Imaging 2010 - Review. PMID 20159661 Free PMC article.
Advances in the imaging and treatment of multiple myeloma have occurred over the past decade. This article summarises the current status and highlights how an understanding of both is necessary for optimum management....
Advances in the imaging and treatment of multiple myeloma have occurred over the past decade. This article summarises the curr …
T cells in multiple myeloma display features of exhaustion and senescence at the tumor site.
Zelle-Rieser C, et al. J Hematol Oncol 2016. PMID 27809856 Free PMC article.
BACKGROUND: Multiple myeloma is an incurable plasma cell malignancy that is mostly restricted to the bone marrow. Cancer-induced dysfunction of cytotoxic T cells at the tumor site may be responsible for immune evasion and therapeutical failure of immunotherapies. ...However, additional avenues to restore anti-myeloma T cell responses are urgently needed....
BACKGROUND: Multiple myeloma is an incurable plasma cell malignancy that is mostly restricted to the bone marrow. Cancer-induc …
Multiple myeloma cancer stem cells.
Gao M, et al. Oncotarget 2016 - Review. PMID 27007154 Free PMC article.
Multiple myeloma (MM) remains incurable despite much progress that has been made in the treatment of the disease. MM cancer stem cell (MMSC), a rare subpopulation of MM cells with the capacity for self-renewal and drug resistance, is considered to lead to disease relapse. ...
Multiple myeloma (MM) remains incurable despite much progress that has been made in the treatment of the disease. MM cancer st
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast.
Reagan MR, et al. Bone 2015 - Review. PMID 25725265 Free PMC article.
Multiple myeloma is a B-cell malignancy characterized by the unrelenting proliferation of plasma cells. Multiple myeloma causes osteolytic lesions and fractures that do not heal due to decreased osteoblastic and increased osteoclastic activity. ...Ultimately, we hope this may provide a roadmap for new approaches to the pathogenesis and treatment of multiple myeloma with a particular focus on the osteoblast....
Multiple myeloma is a B-cell malignancy characterized by the unrelenting proliferation of plasma cells. Multiple mye
4,091 results
Jump to page
Feedback